|
|
|
|
|
On Sept. 7, 2005, the New York Stock Exchange cancelled the planned listing of Huntingdon Life Science's stock, making news headlines around the world. For the first time ever, the Big Board had declined to list a company due to activist pressure. HLS's stock price plumetted, and as financial demos continued over the next six months, HLS saw their finanical picture go from rosy to terminal. Every one of their institutional investors was driven away; every one of their market makers quit doing business with them; they were kicked off of the NASDAQ OTCBB; they were kicked off of the Pink Sheets. Their stock languished on the lowly grey markets, traded by no securities firm, their share price half what it once was in September of 05. Then on Dec. 23, the NYSE buckled to legal pressure from Huntingdon and, in the dead of night and as the market closed for Christmas, began listing LSRI stock on its newly created electronic bulletin board - the NYSE Arca. While it's not the Big Board and carries none of the clout or investment dollars, the NYSE Arca does allow Huntingon's stock to be traded anonymously by individual investors. Perhaps Huntingdon thought they were being clever. Perhaps the New York Stock Exchange thought we wouldn't care enough about their electronic listing of LSRI to make them a top priority. They were wrong. Whever the NYSE goes, we go. To their offices. To their homes. To the doorsteps of their members, shareholders, and directors. Is it really worth it, NYSE? For a stock that trades a dismal average of 1,000 shares a day? From New York to Chicago, from L.A. to San Francisco, from Ohio to D.C., from America to Britain to Belgium, the NYSE and its corporate partners are priority number one. So take close notes on the information below. And NYSE, take close note: we never give in, and we always win.
|
